+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Cancer Supportive Care Drugs Market by Therapeutic Class, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 6010628
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cancer Supportive Care Drugs Market grew from USD 20.62 billion in 2023 to USD 21.46 billion in 2024. It is expected to continue growing at a CAGR of 4.50%, reaching USD 28.06 billion by 2030.

Cancer supportive care drugs play a crucial role in alleviating the adverse effects associated with cancer treatment, such as chemotherapy and radiation, by managing symptoms like nausea, pain, and blood cell deficiencies. These drugs, including antiemetics, analgesics, and hematopoietic agents, are indispensable in improving the quality of life for cancer patients. The necessity for supportive care drugs is underscored by the escalating global cancer burden, leading to increased demand across hospitals, clinics, and other healthcare settings. Key insights into market growth highlight the rise in cancer prevalence, advancements in drug development, and enhanced healthcare infrastructure as significant driving forces. Technological advancements such as precision medicine and personalized healthcare are creating lucrative opportunities, emphasizing the need for innovative therapies that target patient-specific conditions. However, the market faces challenges like high treatment costs, stringent regulatory approvals, and potential side effects of drugs, which might hamper growth. Emerging markets, with their evolving healthcare systems and increasing focus on cancer treatment, present substantial growth opportunities. R&D innovation in non-invasive treatment techniques and targeted drug delivery systems offers promising areas for exploration. Moreover, collaboration between pharmaceutical companies and research institutions is vital in overcoming regulatory and cost barriers. Despite these opportunities, the market's dynamic nature requires stakeholders to remain adept at addressing fluctuations in healthcare policies and economic conditions. To leverage these prospects, businesses should focus on expanding their product portfolios through strategic partnerships and increasing investment in oncology research. Additionally, efforts should be made to ensure affordability and accessibility, which are critical for market penetration in developing regions. As the market continues to evolve, strategic foresight will be crucial for companies aiming to sustain growth and build a robust presence in the cancer supportive care drugs sector.

Understanding Market Dynamics in the Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Rising prevalence of cancer coupled with increase in the geriatric population
    • Increasing approval and launch of new products
    • Increase in R&D activities for development of cancer supportive care drugs
  • Market Restraints
    • High cost of cancer supportive care drugs
  • Market Opportunities
    • Development of novel targeted therapies for the treatment of cancer
    • Rising adoption of biosimilar and increasing government expenditure on healthcare
  • Market Challenges
    • Side effects associated with consumption of drugs

Exploring Porter’s Five Forces for the Cancer Supportive Care Drugs Market

Porter’s Five Forces framework further strengthens the insights of the Cancer Supportive Care Drugs Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Cancer Supportive Care Drugs Market

External macro-environmental factors deeply influence the performance of the Cancer Supportive Care Drugs Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Cancer Supportive Care Drugs Market

The Cancer Supportive Care Drugs Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Supportive Care Drugs Market, highlighting leading vendors and their innovative profiles. These include Acacia Pharma Group PLC, Amgen Inc., Aphios Corporation, AstraZeneca PLC, Bayer AG, Celldex Therapeutics, GSK PLC, Helsinn Healthcare SA, Heron Pharma, Ipsen Pharma, Johnson & Johnson, Merck & Co., Novartis International AG, Sanofi SA, Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Supportive Care Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Therapeutic Class
    • Antiemetics
    • Bisphosphonates
    • Erythropoiesis Stimulating Agents
    • Granulocyte-Colony Stimulating Factors
    • Non-Steroidal Anti-Inflammatory Drugs
    • Opioids
  • Application
    • Breast Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Lung Cancer
    • Prostate Cancer
    • Stomach Cancer
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of cancer coupled with increase in the geriatric population
5.1.1.2. Increasing approval and launch of new products
5.1.1.3. Increase in R&D activities for development of cancer supportive care drugs
5.1.2. Restraints
5.1.2.1. High cost of cancer supportive care drugs
5.1.3. Opportunities
5.1.3.1. Development of novel targeted therapies for the treatment of cancer
5.1.3.2. Rising adoption of biosimilar and increasing government expenditure on healthcare
5.1.4. Challenges
5.1.4.1. Side effects associated with consumption of drugs
5.2. Market Segmentation Analysis
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Cancer Supportive Care Drugs Market, by Therapeutic Class
6.1. Introduction
6.2. Antiemetics
6.3. Bisphosphonates
6.4. Erythropoiesis Stimulating Agents
6.5. Granulocyte-Colony Stimulating Factors
6.6. Non-Steroidal Anti-Inflammatory Drugs
6.7. Opioids
7. Cancer Supportive Care Drugs Market, by Application
7.1. Introduction
7.2. Breast Cancer
7.3. Colorectal Cancer
7.4. Liver Cancer
7.5. Lung Cancer
7.6. Prostate Cancer
7.7. Stomach Cancer
8. Americas Cancer Supportive Care Drugs Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Cancer Supportive Care Drugs Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Cancer Supportive Care Drugs Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.4. Strategy Analysis & Recommendation
LIST OF FIGURES
FIGURE 1. CANCER SUPPORTIVE CARE DRUGS MARKET RESEARCH PROCESS
FIGURE 2. CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 11. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 13. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 15. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 19. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
TABLE 1. CANCER SUPPORTIVE CARE DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CANCER SUPPORTIVE CARE DRUGS MARKET DYNAMICS
TABLE 7. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ANTIEMETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BISPHOSPHONATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY ERYTHROPOIESIS STIMULATING AGENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY GRANULOCYTE-COLONY STIMULATING FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 24. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 25. ARGENTINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 26. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 27. BRAZIL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 28. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 29. CANADA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 30. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 31. MEXICO CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 32. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 33. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 34. UNITED STATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 35. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 36. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 37. ASIA-PACIFIC CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 38. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 39. AUSTRALIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 40. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 41. CHINA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 42. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 43. INDIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 44. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 45. INDONESIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 46. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 47. JAPAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 48. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 49. MALAYSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 50. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 51. PHILIPPINES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 52. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 53. SINGAPORE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 54. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 55. SOUTH KOREA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 56. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 57. TAIWAN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 58. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 59. THAILAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 60. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 61. VIETNAM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 63. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 64. EUROPE, MIDDLE EAST & AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 66. DENMARK CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 67. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 68. EGYPT CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 69. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 70. FINLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 71. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 72. FRANCE CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 73. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 74. GERMANY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 75. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 76. ISRAEL CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 78. ITALY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 79. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 80. NETHERLANDS CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 81. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 82. NIGERIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 83. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 84. NORWAY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 85. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 86. POLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 87. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 88. QATAR CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 89. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 90. RUSSIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 91. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 92. SAUDI ARABIA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 93. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 94. SOUTH AFRICA CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 95. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 96. SPAIN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 97. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 98. SWEDEN CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 99. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 100. SWITZERLAND CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 101. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 102. TURKEY CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 103. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 104. UNITED ARAB EMIRATES CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM CANCER SUPPORTIVE CARE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. CANCER SUPPORTIVE CARE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 108. CANCER SUPPORTIVE CARE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Cancer Supportive Care Drugs market, which are profiled in this report, include:
  • Acacia Pharma Group PLC
  • Amgen Inc.
  • Aphios Corporation
  • AstraZeneca PLC
  • Bayer AG
  • Celldex Therapeutics
  • GSK PLC
  • Helsinn Healthcare SA
  • Heron Pharma
  • Ipsen Pharma
  • Johnson & Johnson
  • Merck & Co.
  • Novartis International AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

Methodology

Loading
LOADING...

Table Information